X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Facilities & Operation

Switzerland Emerges As The Headquarters For European Biotech

Content Team by Content Team
25th May 2023
in Facilities & Operation, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Analysis shows Switzerland has become the chosen headquarters for 20 per cent of European biotech companies. Out of a total of 265 companies that have settled in Switzerland, 63 of them are in the biotech sector, making it the second most significant industry after ICT. This trend is confirmed by statistics from the Swiss federal government in 2022.

A notable aspect is that 23 US companies have established themselves in Basel, Geneva, Zurich, or Lucerne, with several of them being biotech companies that independently market their innovative therapies without extensive support from large pharmaceutical companies. These companies select Switzerland as their European hub.

In preparation for their European launch, emerging biotech companies, responsible for an impressive 65 percent of the molecules in the research and development pipeline in 2022, have made collective decisions regarding infrastructure. These decisions encompass factors such as the engagement model, geographic footprint and structure, degree of centralization, and extent of role specialization.

Switzerland’s appeal to European biotech companies can be attributed to several reasons. Firstly, it offers a business-friendly environment that attracts these companies. Additionally, the country possesses a strong talent pool, including individuals with relevant launch experience at big pharma or other commercial-stage biotech companies. Swissmedic plays a crucial role in supporting innovation and accelerating the approval process for new drugs, even before they are ready for commercialization. This contributes to strengthening Switzerland’s research hub.

Swiss-based biotech companies enjoy a 25 percent higher availability rate for their medicines in European markets compared to the average biotech launches of the past five years. This has led to a growing interest in the Swiss ecosystem from biotech companies, particularly in the last decade. Here also, Swissmedic plays a crucial role in enhancing the Swiss research hub by providing support for innovation and expediting the approval process for new drugs well in advance of their commercialization.

With the assistance of Swissmedic, Switzerland fosters controlled and swift global access to promising products for drug developers through collaborative partnerships with international counterparts. This ensures that patients can benefit quickly from safe and high-quality innovative therapies.

Previous Post

Genomics Market Growth In India To Accelerate Affordability

Next Post

Advancing Pharma Logistics - Smart Contracts And Blockchain

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post

Advancing Pharma Logistics - Smart Contracts And Blockchain

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In